Company Profile: Biocompatibles International plc: local drug delivery for targeted therapies

Abstract

Biocompatibles International plc is focused on the development of targeted therapies for a range of indications, including oncology, neurology and cardiology. By delivering the therapy directly to the site of a localized disease numerous benefits can be achieved, including the targeting of a very high therapeutic dose to the required location and reduced systemic toxicity. As part of this strategy the company is now a leader in the field of using locally placed stem cells to make and deliver therapeutically active peptide drugs. The encapsulated cells (CellBeads®), modified to produce a potent anti-apoptotic peptide, CM1, are currently being evaluated in a Phase I/IIa study for the treatment of stroke and in preclinical models of acute myocardial infarction.